Skip to main content

Table 1 Baseline and clinical characteristics collected from medical records

From: Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Factor n(%)/x ̅±S / M, Q25-Q75
Age 51.130 ± 9.565
BMI 23.83, 22.03–26.17
PLD dose intensity 31.20, 28.99–34.22
ECOG 1 Score 5 (1.1)
Hypertension disease 45 (9.8)
Diabetes 32 (6.9)
Cholecystitis 25 (5.4)
History of gallstones 21 (4.6)
Good peripheral blood circulation 339 (73.5)
Excessive sweat excretion 83 (18.0)
Allergic to the first infusion 23 (5.0)
Viral hepatitis 31 (6.7)
neoadjuvant treatment 128 (27.8)
ER+ 307 (66.6)
PR+ 266 (57.7)
HER-2+ 112 (24.3)
KI-67 high expression 301 (65.3)
Baseline ALT 15, 12–21
Baseline AST 19, 17–23
Baseline GGT 19, 14–26
Baseline TBIL 13, 10–16.35
Baseline MONO 0.37, 0.305–0.45
Baseline NLR 1.75, 1.345–2.365
Baseline PLR 132, 108–170.5
Baseline CA153 9.2, 7–13.7
Baseline CEA 1.64, 1–2.5
  1. KI-67 high expression: Ki67 > 20% was considered high expression
  2. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG eastern cooperative oncology group, ER estrogen receptor, GGT γ-glutamyl transpeptidase, IQR interquartile range, HER2 human epidermalgrowth factor receptor-2, Ki-67 antigen identified by monoclonal antibody Ki-67, MSHFS moderate to severe hand-foot syndrome, MONO monocytes, NLR neutrophil-lymphocyte ratio, NMHFS none and mild hand-foot syndrome, PLR platelet-lymphocyte ratio, PR progesterone receptor, TBIL total bilirubin
\